Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Sai-Hong Ou

Description

Summary

Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC

Official Title

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

Details

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy

Keywords

Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Pembrolizumab, Pemetrexed, Tomivosertib, A1 Tomi + Current Pembro, Pbo + Current Pembro, B1 Tomi + Pembro, Pbo + Pembro

Eligibility

You can join if…

Open to people ages 18 years and up

Inclusion Criteria for Cohort A: Subjects who meet all of the following criteria will be eligible to participate in Cohort A of the study:

  1. Have initiated first-line therapy for NSCLC with pembrolizumab and satisfy the following:
  2. Have tumor PD-L1 ≥1% by 22C3 IHC;
  3. Are judged by the Principal Investigator as tolerating pembrolizumab monotherapy; and
  4. Have been on pembrolizumab for at least 3 months (measured from actual first dose date to first dose date of the current study) and the most recent scans are the first scans to objectively demonstrate Progressive Disease per RECIST 1.1
  5. The first scan conducted a minimum of 21 days after first dose of anti-PD-(L)1 therapy must have shown either SD, PR, or CR (ie, not Progressive Disease) per RECIST 1.1; and
  6. The 2 most recent scans (including 1 demonstrating Progressive Disease) are available to be reviewed

Inclusion Criterion for Cohort B

Subjects who meet the following criterion will be eligible to participate in Cohort B of the study:

  1. Are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance with the package insert and have tumor PD-L1 ≥50% by 22C3 IHC

• Must not have been treated previously with platinum-based chemotherapy in the advanced/metastatic setting. Note: Subjects may have received chemotherapy and/or anti PD (L)1 therapy in the neo/adjuvant setting, provided the last dose of therapy was >9 months prior to randomization.

Subjects who meet the following criterion will be eligible to participate in Cohort C of the study:

  1. Have initiated IL therapy for NSCLC and completed all planned (eg, 4 to 6 cycles) platinum-based chemotherapy with at least 2 cycles in combination with pembrolizumab; must not have had progressive disease on tumor staging imaging scans following completion of all planned platinum chemotherapy
  2. Are eligible for maintenance therapy with pembrolizumab ± pemetrexed in accordance with the package insert
  3. Have tumor PD-L1 ≥1%
  4. The last dose of platinum-based chemotherapy must be within 8 weeks of the first dose of the study drug in this study

Inclusion Criterion for All Cohorts

  • Subjects must also meet all of the following criteria to be eligible to participate in the study:
  • Have histologically confirmed NSCLC that is inoperable, locally advanced or metastatic (Stage IIIb/IV)
  • Have available at the site a representative formalin-fixed, paraffin-embedded tumor specimen that enabled diagnosis of NSCLC in a tissue block (preferred) or 10 unstained, serial slides, accompanied by an associated pathology report. Note: If the archival tissue is neither sufficient nor available, the subject may still be eligible, upon discussion with the Medical Monitor
  • Have provided written informed consent and any authorizations required by local law
  • Are ≥18 years of age
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You CAN'T join if...

  1. Have NSCLC with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
  2. Have gastrointestinal (GI) disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, and/or bowel obstruction) that may interfere with drug absorption or with interpretation of GI AEs
  3. Have known symptomatic brain metastases requiring >10 mg/day of prednisone (or its equivalent). Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to randomization, fulfill the steroid requirement for these metastases, the 2 most recent serial magnetic resonance imaging (MRI) scans conducted >28 days apart show no central nervous system progression, and are neurologically stable and asymptomatic

Locations

  • University of California - Irvine Medical Center accepting new patients
    Irvine California 92868-3298 United States
  • Keck Medicine of USC Norris Oncology/Hematology accepting new patients
    Newport Beach California 92663 United States
  • Pacific Shores Medical Group accepting new patients
    Long Beach California 90813 United States
  • American Institute of Research accepting new patients
    Whittier California 90603 United States

Lead Scientist at UC Irvine

  • Sai-Hong Ou
    Health Sciences Professor, Medicine, School of Medicine. Authored (or co-authored) 6 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Effector Therapeutics
ID
NCT04622007
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 180 study participants
Last Updated